Skip to main content
IVVD logo

IVVD · Invivyd, Inc. · Investor Relations

Track IVVD — free
$0.41 -0.03 (-7.45%) At close · Nov 20 Play latest call Q1 2026 earnings call transcript
Market Cap
$122.01M
Shares
295.63M
Volume · Nov 20 5.32M Avg daily vol (3M) 5.21M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-03 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-21 Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
2026-10-14 Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
2026-10-05 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
2026-09-01 Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
2026-08-13 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-06 Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
2026-05-14 Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-09 Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
2026-03-05 Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
2026-01-08 Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
2025-12-23 Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
2025-11-24 Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
2025-11-19 Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
2025-11-19 Invivyd Announces Proposed Public Offering of Common Stock
2025-11-06 Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Past events

Source: https://investors.invivyd.com/

Key facts CIK 1832038 CUSIP 00534A102 13F (30d) 144 filings 126 filers Visit website Investor relations